LEGN.US.EQUI (LEGN.US.EQUI) News
Follow LEGN.US.EQUI (LEGN.US.EQUI) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 2 public stories across 2 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Legend Biotech just downgraded at UBS, here's why
Legend Biotech just downgraded at UBS, here's why
EQUITY | Jul 24, 2026, 08:26 AM UTC
H
Legend Biotech price target lowered to $63 from $64 at RBC Capital
RBC Capital analyst Leonid Timashev lowered the firm's price target on Legend Biotech to $63 from $64 and keeps an Outperform rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The
EQUITY | Jul 07, 2026, 11:31 AM UTC